BioCentury | Dec 6, 2019
Targets & Mechanisms
Emerging immuno-oncology mechanisms at ASH 2019
...expansion will perform in CLL patients. Another emerging T cell inhibitory protein, the checkpoint protein BTLA...
...abstracts describe manipulation of BTLA as a therapeutic target, at least two companies are developing anti-BTLA...
...cells (see “NK Cell Check-in” ). Targets AMPD1 - Adenosine monophosphate deaminase 1 BTLA - B and T lymphocyte attenuator...
...abstracts describe manipulation of BTLA as a therapeutic target, at least two companies are developing anti-BTLA...
...cells (see “NK Cell Check-in” ). Targets AMPD1 - Adenosine monophosphate deaminase 1 BTLA - B and T lymphocyte attenuator...